Please login to the form below

Not currently logged in
Email:
Password:

Inrebic

This page shows the latest Inrebic news and features for those working in and with pharma, biotech and healthcare.

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

It also comes on the heels of  another significant approval of Celgene’s JAK inhibitor Inrebic (fedratinib), which scored an FDA nod in August. ... Some analysts have predicted that Inrebic could also become a $1bn product in myelofibrosis, despite a

Latest news

  • Roche agrees $1.4bn takeover of fibrosis specialist Promedior Roche agrees $1.4bn takeover of fibrosis specialist Promedior

    anaemia. The only marketed therapies for myelofibrosis are currently Incyte/Novartis’ Jakafi (ruxolitinib), a $1.4bn JAK 1/2 inhibitor first approved in 2011, and Celgene’s newer JAK inhibitor  Inrebic ... Some analysts think Inrebic could become a

  • BMS buoyed by FDA approval of Celgene’s myelofibrosis drug BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

    Currently in the middle of merger. After a turbulent development, Celgene has finally claimed FDA approval for Inrebic, its new drug for rare bone marrow disorder myelofibrosis. ... Inrebic (fedratinib) is the second JAK inhibitor to be approved for

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics